Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort

被引:14
|
作者
Horn-Ross, Pamela L. [1 ]
Canchola, Alison J. [1 ]
Bernstein, Leslie [3 ]
Neuhausen, Susan L. [3 ]
Nelson, David O. [2 ]
Reynolds, Peggy [2 ,4 ]
机构
[1] Canc Prevent Inst Calif, 2201 Walnut Ave,Suite 300, Fremont, CA 94538 USA
[2] Canc Prevent Inst Calif, 2001 Ctr St,Suite 700, Berkeley, CA 94704 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, 1500 Duarte Rd, Duarte, CA 91010 USA
[4] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Div Epidemiol, 150 Governors Lane, Stanford, CA 94305 USA
来源
BREAST CANCER RESEARCH | 2016年 / 18卷
关键词
Breast cancer; Body size; Obesity; Adiposity; Body fat distribution; Height; Life course; ADULT WEIGHT CHANGE; NEW-YORK; WOMEN; PREMENOPAUSAL; PROGESTIN; ADIPOSITY; HEALTH; SHAPE;
D O I
10.1186/s13058-016-0790-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Obesity is a public health epidemic and an important breast cancer risk factor. The relationship between interrelated body measurements is complex and most studies fail to account for this complexity. We identified key aspects of body size which jointly, over the life-course (since adolescence), are associated with estrogen-receptor-positive (ER+) breast cancer risk. Methods: Among 109,862 women participating in the California Teachers Study cohort, 3844 were diagnosed with invasive ER+ breast cancer between 1997-1998 and December 2011. Based on validated self-reported height and weight at age 18, baseline, and 10-year follow up and waist circumference at 2-year and 10-year follow up, we identified 16 a priori body-size phenotypes. Multivariable Cox proportional hazards models provided estimates of hazard rate ratios (HR) and 95% confidence intervals (CI). Results: Premenopausal breast cancer was influenced by adolescent, but not adult, body size (HR = 0.51, 95% CI 0. 31-0.86 for body mass index (BMI; kg/m(2)) >= 25 vs < 20 at age 18). Among postmenopausal women currently using hormone therapy, only those with the greatest body size had increased breast cancer risk (HR = 1.36, 95% CI 1.13-1. 64 for height >= 67 inches and adult BMI >= 25 vs height < 67). Among postmenopausal women not currently using hormone therapy, the relationship between body size and risk was complex, with the largest effects of adiposity among short women. Among short women, those with gluteal adiposity (HR = 2.70, 95% CI 1.77-4.10) and those who continued to gain weight throughout adulthood (HR = 2.57, 95% CI 1.60-4.12) were at greatest risk, whereas those who had been overweight/obese since adolescence were not at increased risk (HR = 1.33, 95% CI 0.84-2.10). Height was associated with a small increased risk, with borderline statistical significance. Conclusions: Considering absolute body mass in adolescence and at two points in adulthood, dynamic changes in adiposity over time, and body fat distribution, we identified obesity phenotypes associated with ER+ breast cancer risk. Our approach more clearly identifies specific risk groups than do analyses that evaluate similar measures separately. These findings may aid in improving risk prediction models and developing targeted interventions, and may clarify inconsistent findings across studies.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers
    Nath, Aritro
    Cohen, Adam L.
    Bild, Andrea H.
    MOLECULAR SYSTEMS BIOLOGY, 2022, 18 (06)
  • [42] ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
    Xu, Guotai
    Chhangawala, Sagar
    Cocco, Emiliano
    Razavi, Pedram
    Cai, Yanyan
    Otto, Jordan E.
    Ferrando, Lorenzo
    Selenica, Pier
    Ladewig, Erik
    Chan, Carmen
    Paula, Arnaud Da Cruz
    Witkin, Matthew
    Cheng, Yuanming
    Park, Jane
    Serna-Tamayo, Cristian
    Zhao, HuiYong
    Wu, Fan
    Sallaku, Mirna
    Qu, Xuan
    Zhao, Alison
    Collings, Clayton K.
    D'Avino, Andrew R.
    Jhaveri, Komal
    Koche, Richard
    Levine, Ross L.
    Reis-Filho, Jorge S.
    Kadoch, Cigall
    Scaltriti, Maurizio
    Leslie, Christina S.
    Baselga, Jose
    Toska, Eneda
    NATURE GENETICS, 2020, 52 (02) : 198 - +
  • [43] Body size and breast cancer risk: The multiethnic cohort
    White, Kami K.
    Park, Song-Yi
    Kolonel, Laurence N.
    Henderson, Brian E.
    Wilkens, Lynne R.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (05) : E705 - E716
  • [44] Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
    Miller, Christopher A.
    Gindin, Yevgeniy
    Lu, Charles
    Griffith, Obi L.
    Griffith, Malachi
    Shen, Dong
    Hoog, Jeremy
    Li, Tiandao
    Larson, David E.
    Watson, Mark
    Davies, Sherri R.
    Hunt, Kelly
    Suman, Vera J.
    Snider, Jacqueline
    Walsh, Thomas
    Colditz, Graham A.
    DeSchryver, Katherine
    Wilson, Richard K.
    Mardis, Elaine R.
    Ellis, Matthew J.
    Nature Communications, 2016, 7
  • [45] Radiation Without Endocrine Therapy in Older Women With Stage I Estrogen-Receptor-Positive Breast Cancer is Not Associated With a Higher Risk of Second Breast Cancer Events
    Gerber, Naamit K.
    Shao, Huibo
    Chadha, Manjeet
    Deb, Partha
    Gold, Heather T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (01): : 40 - 51
  • [46] Meta analysis of the second collaborative study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in patients with stage II, estrogen-receptor-positive breast cancer
    Yoshida M.
    Abe O.
    Uchino J.
    Kikuchi K.
    Abe R.
    Enomoto K.
    Tominaga T.
    Fukami A.
    Sugimachi K.
    Nomura Y.
    Hattori T.
    Ogawa N.
    Breast Cancer, 1997, 4 (2) : 93 - 101
  • [47] Risk factors for estrogen receptor-positive breast cancer
    Hwang, ES
    Chew, T
    Shiboski, S
    Farren, G
    Benz, CC
    Wrensch, M
    ARCHIVES OF SURGERY, 2005, 140 (01) : 58 - 62
  • [48] Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer (vol 12, 599586, 2021)
    Belachew, Esmael Besufikad
    Sewasew, Dareskedar Tsehay
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [49] Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
    Christopher A. Miller
    Yevgeniy Gindin
    Charles Lu
    Obi L Griffith
    Malachi Griffith
    Dong Shen
    Jeremy Hoog
    Tiandao Li
    David E. Larson
    Mark Watson
    Sherri R Davies
    Kelly Hunt
    Vera J. Suman
    Jacqueline Snider
    Thomas Walsh
    Graham A. Colditz
    Katherine DeSchryver
    Richard K. Wilson
    Elaine R. Mardis
    Matthew J. Ellis
    Nature Communications, 7
  • [50] Vessel size as a marker of survival in estrogen receptor positive breast cancer
    Vladan Milosevic
    Reidunn J. Edelmann
    Ingeborg Winge
    Carina Strell
    Artur Mezheyeuski
    Gøril Knutsvik
    Cecilie Askeland
    Elisabeth Wik
    Lars A. Akslen
    Arne Östman
    Breast Cancer Research and Treatment, 2023, 200 : 293 - 304